The study of BCMA-CD19 cCAR T Cell Treatment of Systemic Lupus Erythematosus

The company iCell Gene Therapeutics is commencing recruitment for the clinical trial of the BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE).

The condition is Relapsed/Refractory, Systemic Lupus Erythematosus (SLE).

A new clinical trial is recruiting patients in the following locations: China.

The trial officially began on the April 1, 2022 and is planned to complete on April 30, 2025.

iCAR Bio Therapeutics Ltd. China is the collaborator in this clinical trial.

The link to the complete study profile:

Clinical Research News

Upcoming Clinical Trials